Aktienanalyse zu Silo Pharma Inc (SILO)SILOSilo Pharma Inc

Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis. It operates in the Healthcare sector (APPAREL & OTHER FINISHD PRODS OF FABRICS & SIMILAR industry).

Silo Pharma Inc is a good buy right now due to its recent patent allowances for SPC-15, which enhance its market position and potential for future revenue. The current price is $1.33, and the stock has shown a 5-day change of +8.13%, indicating positive momentum. However, the company has a high forward P/E of 0, reflecting uncertainty in earnings projections, and a significant risk is its year-to-date change of -73.58%, indicating past performance volatility.